Andrea de Castro

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.